Our study focused on fabricating and characterizing a crocin in situ forming hydrogel for endometriosis treatment. An artificial neural network (ANN)-based machine learning (ML) approach was employed to determine the …
Female fertility has long been explained through observation of the ovarian follicle: the number of residing follicles and the quality of the oocyte. This review argues that the tissue surrounding …
Fibrosis is a common pathological feature of inflammatory conditions across various organ systems, leading to a marked increase in matrix stiffness. The effects of substrate stiffness on benign epithelial cells …
Endometriosis (EM) is a chronic, estrogen-dependent inflammatory disease affecting approximately 10% of women of reproductive age worldwide, causing debilitating pelvic pain, infertility, and substantially impaired quality of life. Conventional hormonal …
Stem cell-based models resembling murine blastocysts represent a useful system to investigate subsequent developmental processes. While existing cell lines derived from epiblast and trophectoderm can be aggregated to form 'blastoids', …
Endometriosis is a chronic, systemic inflammatory disorder characterized by the ectopic implantation of endometrial-like tissue and accompanied by persistent pain and infertility. Beyond the pelvis, accumulating epidemiological evidence indicates that …
Endometriosis-associated pelvic pain represents a prototypical failure of systemic therapy for a locally organized, neuroinflammatory disease. Persistent pain arises from the convergence of estrogen-driven lesion survival, chronic inflammation, fibrosis, and …
Fibroblast growth factor receptor 2 (FGFR2) has emerged as a highly promising therapeutic target due to its critical role in the pathogenesis and progression of endometriosis. To date, a variety …
The ascent of novel alternative methods in drug development spotlights the dual needs for improved biological fidelity to in vivo, along with reproducibility, especially in regulatory applications. The need for …
Elagolix sodium (ELS), a non-peptide oral gonadotropin-releasing hormone receptor (GnRH) antagonist approved for the treatment of endometriosis-associated pain, displays atypical gelation in aqueous environments along with challenging physical properties such …